Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

Fig. 2

Cost-effectiveness plane of the ICER estimates (top) and cost-effectiveness acceptability curve (bottom) from the PSA for DAPA + MET versus DPP-4i + MET. ICER threshold at £20,000 is represented by the red dashed line in the top panel. Analysis of the PSA result suggested that DAPA + MET had an 85 % probability of being cost-effective at this threshold.

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us